ivermectin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
ivermectin: clinical details
Prescribing considerations
- Confirm scabies clinically or parasitologically; pruritus alone does not justify oral ivermectin.
- Review residence or travel in Loa loa-endemic regions before systemic treatment because heavy coinfection increases encephalopathy risk.
- Evidence is inadequate for uncomplicated intestinal strongyloidiasis in immunocompromised patients; persistent infection may occur.
- Safety of oral products is not established below 15 kg body weight.
- Facial cream is licensed for adults; use caution in severe hepatic impairment.
- Do not use ivermectin to treat or prevent COVID-19.
Contraindications and cautions
- Hypersensitivity to ivermectin or any formulation excipient.
- Do not restart oral ivermectin after ivermectin-associated Stevens–Johnson syndrome or toxic epidermal necrolysis.
Monitoring
- Assess promptly for severe skin reactions, neurological toxicity or hypersensitivity.
- Tailor follow-up to the parasite and confirm clearance where clinically appropriate, particularly in immunocompromised patients.
- Consider liver assessment if symptoms or laboratory findings suggest hepatic injury.
- For rosacea, review severe early worsening or lack of meaningful clinical response.
Clinical pharmacology
Oral ivermectin is absorbed systemically, metabolised mainly through CYP3A4 and excreted predominantly in faeces. Topical absorption is low but measurable. Antiparasitic activity results from activation of invertebrate glutamate-gated chloride channels; its rosacea mechanism may combine anti-inflammatory activity with effects on Demodex mites.
Formulation and product differences
- Tablets provide systemic exposure and are licensed for selected helminth infections and confirmed scabies.
- Cream is restricted to facial use for inflammatory rosacea lesions in adults.
- Cream excipients include cetyl alcohol, stearyl alcohol, parabens and propylene glycol, which may cause irritation, contact dermatitis or delayed allergy.
ivermectin preparations and strengths
Cream
Route: Cutaneous
Strengths: 10 mg/g
Tablet
Route: Oral
Strengths: 3 mg
ivermectin interactions
Interaction evidence is limited. The prescriber should review all medicines and supplements.
Potent CYP3A4 inhibitors
These may increase systemic exposure to ivermectin from the cream; caution is required.
Diethylcarbamazine citrate
Combined systemic use in people with certain filarial coinfections may provoke serious inflammatory or neurological reactions and is not recommended in relevant mass-treatment settings.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.